FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2258565818> ?p ?o ?g. }

• W2258565818 endingPage "9023" @default.
• W2258565818 startingPage "9023" @default.
• W2258565818 abstract "9023 Background: Nonhormonal pharmacologic interventions are recommended for the treatment of HF in breast cancer survivors. Antidepressants (SSRI/SNRI) and G have been shown to be effective, however, it is still unclear which agent is best. Methods: A randomized crossover trial compared 4 weeks of V (37.5 mg × 7 days followed by 75 mg/day) and G (300 mg daily × 3 days, 300 mg BID × 3 days then 300 mg TID). Eligibility included postmenopausal women with at least 14 bothersome HF per week for the prior month. A 2-week baseline period was followed by the first treatment period. Crossover to the alternative treatment occurred following a 2 week dose tapering/wash out period. The primary endpoint was patient preference. Secondary endpoints included change from baseline in HF score (frequency × severity) per a prospective daily HF diary, change in HF frequency, QOL, mood and toxicity. Toxicities were evaluated with a self-report questionnaire and NCI common terminology criteria. A two-stage group sequential design was used with the first analysis pre-planned at 66 patients and the second (if needed) at 131, allowing for drop out/indecision rate of 25%. The design had 80% power to detect a shift from equal preference of ≥ 15 % (2 sided type 1 error at 5%). Results: Data analysis after 66 patients showed the pre-defined stopping rule was satisfied. The study arms were well balanced. Of 56 patients with a preference (8 dropped out and 2 had no preference), 18 preferred G and 38 preferred V (32% and 68% respectively; p = 0.01). Both V and G reduced HF scores (66% reduction) and frequency (55% reduction) similarly and significantly. Satisfaction with the preferred treatment was high. V was associated with more appetite loss, nausea and constipation, and less sleeplessness, nervousness, and negative mood changes than at baseline (all p ≤ 0.03) whereas G was associated with more dizziness and increased appetite, and less sleeplessness (all p ≤ 0.004). Conclusions: Breast cancer survivors prefer V over G for the treatment of HF. Both agents are effective in the management of HF based on recorded diary experience. Preference appears to be driven by the balance between effectiveness and tolerance. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, GlaxoSmithKline, Novartis, Roche Amgen, AstraZeneca, GlaxoSmithKline, Novartis, Roche AstraZeneca" @default.
• W2258565818 created "2016-06-24" @default.
• W2258565818 creator A5008767553 @default.
• W2258565818 creator A5032255536 @default.
• W2258565818 creator A5033831143 @default.
• W2258565818 creator A5039085454 @default.
• W2258565818 creator A5059321337 @default.
• W2258565818 creator A5071294954 @default.
• W2258565818 creator A5076245140 @default.
• W2258565818 creator A5080349429 @default.
• W2258565818 date "2010-05-20" @default.
• W2258565818 modified "2023-09-27" @default.
• W2258565818 title "A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors." @default.
• W2258565818 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.9023" @default.
• W2258565818 hasPublicationYear "2010" @default.
• W2258565818 type Work @default.
• W2258565818 sameAs 2258565818 @default.
• W2258565818 citedByCount "1" @default.
• W2258565818 countsByYear W22585658182019 @default.
• W2258565818 crossrefType "journal-article" @default.
• W2258565818 hasAuthorship W2258565818A5008767553 @default.
• W2258565818 hasAuthorship W2258565818A5032255536 @default.
• W2258565818 hasAuthorship W2258565818A5033831143 @default.
• W2258565818 hasAuthorship W2258565818A5039085454 @default.
• W2258565818 hasAuthorship W2258565818A5059321337 @default.
• W2258565818 hasAuthorship W2258565818A5071294954 @default.
• W2258565818 hasAuthorship W2258565818A5076245140 @default.
• W2258565818 hasAuthorship W2258565818A5080349429 @default.
• W2258565818 hasConcept C121608353 @default.
• W2258565818 hasConcept C126322002 @default.
• W2258565818 hasConcept C142724271 @default.
• W2258565818 hasConcept C168563851 @default.
• W2258565818 hasConcept C197934379 @default.
• W2258565818 hasConcept C203092338 @default.
• W2258565818 hasConcept C204787440 @default.
• W2258565818 hasConcept C27081682 @default.
• W2258565818 hasConcept C2777793932 @default.
• W2258565818 hasConcept C530470458 @default.
• W2258565818 hasConcept C71924100 @default.
• W2258565818 hasConcept C87813604 @default.
• W2258565818 hasConceptScore W2258565818C121608353 @default.
• W2258565818 hasConceptScore W2258565818C126322002 @default.
• W2258565818 hasConceptScore W2258565818C142724271 @default.
• W2258565818 hasConceptScore W2258565818C168563851 @default.
• W2258565818 hasConceptScore W2258565818C197934379 @default.
• W2258565818 hasConceptScore W2258565818C203092338 @default.
• W2258565818 hasConceptScore W2258565818C204787440 @default.
• W2258565818 hasConceptScore W2258565818C27081682 @default.
• W2258565818 hasConceptScore W2258565818C2777793932 @default.
• W2258565818 hasConceptScore W2258565818C530470458 @default.
• W2258565818 hasConceptScore W2258565818C71924100 @default.
• W2258565818 hasConceptScore W2258565818C87813604 @default.
• W2258565818 hasIssue "15_suppl" @default.
• W2258565818 hasLocation W22585658181 @default.
• W2258565818 hasOpenAccess W2258565818 @default.
• W2258565818 hasPrimaryLocation W22585658181 @default.
• W2258565818 hasRelatedWork W2061017850 @default.
• W2258565818 hasRelatedWork W2085488843 @default.
• W2258565818 hasRelatedWork W2225638675 @default.
• W2258565818 hasRelatedWork W2530830155 @default.
• W2258565818 hasRelatedWork W2956014051 @default.
• W2258565818 hasRelatedWork W3096997298 @default.
• W2258565818 hasRelatedWork W3135313725 @default.
• W2258565818 hasRelatedWork W3180086826 @default.
• W2258565818 hasRelatedWork W4210534274 @default.
• W2258565818 hasRelatedWork W4226051264 @default.
• W2258565818 hasVolume "28" @default.
• W2258565818 isParatext "false" @default.
• W2258565818 isRetracted "false" @default.
• W2258565818 magId "2258565818" @default.
• W2258565818 workType "article" @default.